Agenda
London, 17 - 18 March 2026
Schedule
Create your personal agenda –check the favourite icon
Mar 178:59
Conference pass
Welcome Remarks
Keynotes
Chris Shanks, Content Director, Terrapinn Holdings Ltd
Mar 179:00
Conference pass
Chair’s Opening Remarks
Keynotes
Mark Battaglini, Chief Strategy Officer, Alliance for Regenerative Medicine
Mar 179:05
Conference pass
Past, Present and Future of Gene Therapy: How far have we come?
Keynotes
Bobby Gaspar, Chief Executive Officer, Orchard Therapeutics
Mar 179:45
Conference pass
Keynote Panel Discussion: Navigating the Cell and Gene Therapy Landscape: Opportunities & Challenges for Driving Market Success
Keynotes
Moderator: Mark Battaglini, Chief Strategy Officer, Alliance for Regenerative Medicine
Chris Williams, Chief Business Officer, Autolus
Ana Plata, Head of Global Access, Respiratory & Immunology, Astrazeneca
Peter Andersen, Chief Research & Development Officer, Treefrog Therapeutics
Claire Kerridge, Head of Gene Therapy, MHRA
Luke Henry, Chief Business Officer, Quell Therapeutics
Nan Zhang, Chief, Cell Therapy Manufacturing Section, Center for Cellular Engineering, National Institutes of Health
Jay Feinberg, President, World Marrow Donor Association
Mar 1711:25
Conference pass
Chair’s Remarks: Alexander Natz, Secretary General, European Confederation of Pharmaceutical Entrepreneurs
Evidence, Pricing & Access (Track 1)
Mar 1711:25
Conference pass
Chair's Remarks: Alain Wagner, Director of Research, CNRS
Immunotherapy (Track 5)
Alain Wagner, Director of Research, CNRS
Mar 1711:25
Conference pass
Chair's Remarks: Chris Baldwin, Vice President, Manufacturing and Supply, Resolution Therapeutics
Supply Chain & Logistics (Track 4)
Chris Baldwin, Vice President, Manufacturing & Supply, Resolution Therapeutics
Mar 1711:25
Conference pass
Chair's Remarks: Katie Binley, Chief Scientific Officer, ikarovec
Gene Therapy (Track 7)
Katie Binley, Chief Scientific Officer, ikarovec
Mar 1711:25
Conference pass
Chair's Remarks: Manuel Teixeira Carrondo, Vice-President, iBET
Cell Therapy Manufacturing (Track 10)
Manuel Carrondo, Vice-President, iBET: Instituto de Biologia Experimental e Tecnológica
Mar 1711:25
Conference pass
Chair's Remarks: Miguel Forte, CEO, Kiji Tx
Gene Modified Cell Therapy (Track 8)
Mar 1711:25
Conference pass
Chair's Remarks: Raphael G. Ognar, President & CEO, Co-founder, NKILT Therapeutics
Cell Therapy (Track 3)
Raphael Ognar, 5, NKILT Therapeutics Inc.
Mar 1711:25
Conference pass
Chair's Remarks: Roberto Gramignoli, Associate Professor, Karolinska Institute Head UOSD and Director of Lab of Cell Therapies, Gaslini Hospital
Innovation (Track 2)
Roberto Gramignoli, Associate Professor, Karolinska Institutet
Mar 1711:25
Conference pass
Chair's Remarks: Sophie Mountcastle, Programme Manager, Medical Research Council
Viral Vector Manufacturing Sponsored by Fujifilm Diosynth Biotechnologies (Track 9)
Mar 1711:30
Conference pass
Behind Allogeneic Cell Therapy: The Critical Role of Donor Registries and the WMDA in Starting Material
Supply Chain & Logistics (Track 4)
Jay Feinberg, President, World Marrow Donor Association
Mar 1711:30
Conference pass
Building a scalable iPSC platform for the future
Cell Therapy Manufacturing (Track 10)
Peter Andersen, Chief Research & Development Officer, Treefrog Therapeutics
Mar 1711:30
Conference pass
Building an academic pipeline
Innovation (Track 2)
Pamela Tranter, Head, Translational Research Group (TRO), University College London
Mar 1711:30
Conference pass
Cell therapy optimisation: Sourcing and engineering
Gene Modified Cell Therapy (Track 8)
Mar 1711:30
Conference pass
Evidence and Access challenges for CAR-T therapies across Europe
Evidence, Pricing & Access (Track 1)
Brett Doble, Director HEOR, Australia/Canada/Europe (ACE), HEOR Center of Excellence, Kite, a Gilead Company
Mar 1711:30
Conference pass
Gene therapy for kidney disease
Gene Therapy (Track 7)
Moin Saleem, Founder and Chief Scientific Advisor, Purespring Therapeutics
Mar 1711:30
Conference pass
Leveraging CIR technology to accelerate and improve access to off-the-shelf cell therapies for cancer patients
Cell Therapy (Track 3)
Raphael Ognar, 5, NKILT Therapeutics Inc.
Mar 1711:30
Conference pass
Mar 1711:30
Conference pass
Transforming Gene Therapy: Stable Producer Cell Lines as the Future of Lentiviral Vector Manufacturing
Viral Vector Manufacturing Sponsored by Fujifilm Diosynth Biotechnologies (Track 9)
Holger Laux, Director of Genetic Medicine, CSL Behring
Mar 1711:50
Conference pass
Creating sophisticated gene therapy solutions for chronic eye diseases
Gene Therapy (Track 7)
Katie Binley, Chief Scientific Officer, ikarovec
Mar 1711:50
Conference pass
Digital models, shadows and twins for improving ATMP manufacturing
Gene Modified Cell Therapy (Track 8)
Joseph Egan, Research Associate, Teesside University
Mar 1711:50
Conference pass
Engineering the biology of AAV secretion
Viral Vector Manufacturing Sponsored by Fujifilm Diosynth Biotechnologies (Track 9)
Darren Nesbeth, Associate Professor, University College London
Mar 1711:50
Conference pass
Expansion of autologous regulatory T-cells for treatment of Idiopathic Aplastic Anaemia patients: Insights on the TIARA Trial
Immunotherapy (Track 5)
Nazia Matto, sATMP scientist, GMP Facility, Tower wing, Guys Hospital
Mar 1711:50
Conference pass
How to develop cell therapy programs in Latin America?
Cell Therapy (Track 3)
Alejandro Madrigal, OBE FMedSci, Professor of Haematology, UCL Cancer Institute
Mar 1711:50
Conference pass
New perinatal stem cell therapies without immuno suppression
Innovation (Track 2)
Roberto Gramignoli, Associate Professor, Karolinska Institutet
Mar 1711:50
Conference pass
Operational considerations for cell therapy manufacturing
Supply Chain & Logistics (Track 4)
Mar 1711:50
Conference pass
Tailored yet alike? Process development similarities leading to platforms across cell therapies
Cell Therapy Manufacturing (Track 10)
Manuel Carrondo, Vice-President, iBET: Instituto de Biologia Experimental e Tecnológica
Mar 1711:50
Conference pass
Update on the European and US Ecosystem for cell and gene therapies: What does the future of ATMP policy and access look like
Evidence, Pricing & Access (Track 1)
Mar 1712:10
Conference pass
Approaches to innate immunotherapy
Immunotherapy (Track 5)
Hugh JM Brady, Professor of Immunology, Imperial College London
Mar 1712:10
Conference pass
Regenerative Macrophage Therapy for Inflammatory and Fibrotic Diseases
Gene Modified Cell Therapy (Track 8)
Victor Dillard, VP, Strategy & Operations, Resolution Therapeutics
Mar 1713:30
Conference pass
Chair’s Remarks: David Morrow, Senior Scientific Programme Manager-ATMP/Vaccines, EATRIS
Innovation (Track 2)
David Morrow, Senior Scientific Programme Manager-ATMP/Vaccines, EATRIS
Mar 1713:30
Conference pass
Chair’s Remarks: Nicola Redfern, Director, NJ Redfern Ltd.
Evidence, Pricing & Access (Track 1)
Nicola Redfern, Director, NJ Redfern Ltd.
Mar 1713:30
Conference pass
Chair's Remarks: Brian Harrison, Managing Director, HiTech Health
Supply Chain & Logistics (Track 4)
Brian Harrison, Director, Hitech Health
Mar 1713:30
Conference pass
Chair's Remarks: Eric David, Chief Executive Officer of Gene Therapy, BridgeBio
Gene Therapy (Track 7)
Eric Michael David, Chief Executive Officer of Gene Therapy, BridgeBio
Mar 1713:30
Conference pass
Chair's Remarks: Gerty Schreibelt, Assistant Professor / Immunologist, Radboud University Medical Centre
Immunotherapy (Track 5)
Gerty Schreibelt, Assistant Professor / Immunologist, Radboud University Medical Centre
Mar 1713:30
Conference pass
Chair's Remarks: Harris Makatsoris, Professor of Manufacturing, King’s College London
Cell Therapy Manufacturing (Track 10)
Harris Makatsoris, Professor of Manufacturing, King's College London
Mar 1713:30
Conference pass
Chair's Remarks: Kerstin Papenfuss, Director Pharma, Deep Science Ventures
Start-ups Showcase (Track 6)
Kerstin Papenfuss, Director Pharma, Deep Science Ventures
Mar 1713:30
Conference pass
Chair's Remarks: Marcus Droege, Chief Commercial Officer, MUVON Therapeutics AG
Cell Therapy (Track 3)
Marcus Droege, Chief Commercial Officer, MUVON Therapeutics
Mar 1713:30
Conference pass
Chair's Remarks: Patricia Longo, CMC Sr. Staff Scientist, Regeneron
Viral Vector Manufacturing Sponsored by Fujifilm Diosynth Biotechnologies (Track 9)
Patricia Longo, CMC Sr. Staff Scientist, Regeneron
Mar 1713:30
Conference pass
Chair's Remarks: Stefanos Theoharis, Chief Executive Officer, OneChain Immunotherapeutics
Gene Modified Cell Therapy (Track 8)
Stefanos Theoharis, Chief Executive Officer, OneChain Immunotherapeutics
Mar 1713:35
Conference pass
Clinical development of NK cell therapies
Cell Therapy (Track 3)
Monica Raimo, Director of Product and Process Development, Glycostem Therapeutics
Mar 1713:35
Conference pass
Comparability assessments for AAV process changes
Viral Vector Manufacturing Sponsored by Fujifilm Diosynth Biotechnologies (Track 9)
Patricia Longo, CMC Sr. Staff Scientist, Regeneron
Mar 1713:35
Conference pass
Engineering potent cellular therapies by modulating morphogenic signalling pathways
Gene Modified Cell Therapy (Track 8)
Mar 1713:35
Conference pass
New methods for detecting replication competent AAV for gene therapy
Gene Therapy (Track 7)
Mar 1713:35
Conference pass
Operational considerations of using cord blood as a cell therapy starting material
Supply Chain & Logistics (Track 4)
Alex Ross, Head of NHS Cord Bank, NHS Blood and Transplant
Mar 1713:35
Conference pass
Point of care manufacturing: Challenges & Opportunities
Cell Therapy Manufacturing (Track 10)
Sandeep Kumar, Head of Advanced Therapy Production, Guy's and St Thomas' NHS Foundation Trust
Mar 1713:35
Conference pass
Resilience by Design: Alternative Financial Models for Funding
Start-ups Showcase (Track 6)
James Levine, President, Fondation Ipsen
Mar 1713:35
Conference pass
Reversing TIL cell exhaustion in solid tumours
Immunotherapy (Track 5)
David Peritt, Chief Scientific Officer, Lupagen
Mar 1713:35
Conference pass
The bumpy and uncertain road to access in the Netherlands
Evidence, Pricing & Access (Track 1)
Henriette Burghoorn, Associate Director, Market Access, Gilead Sciences
Mar 1713:35
Conference pass
Where are we heading with exosomes?
Innovation (Track 2)
David Kuntin, Chief Executive Officer, Mesenbio
Mar 1713:55
Conference pass
Monitoring of immune response with single cell technologies
Immunotherapy (Track 5)
Alain Wagner, Director of Research, CNRS
Mar 1714:15
Conference pass
CMC perspectives for supply of ATMPs
Supply Chain & Logistics (Track 4)
Ross Bunyan, External Manufacturing Lead, Resolution Therapeutics
Mar 1714:15
Conference pass
Delivering next generation treatment for cancer
Immunotherapy (Track 5)
Mar 1714:15
Conference pass
Development of mesenchymal stromal cell therapy for type 1 diabetes
Cell Therapy (Track 3)
Mar 1714:15
Conference pass
Development of novel gene regulatory elements for CNS gene therapy
Gene Therapy (Track 7)
Mar 1714:15
Conference pass
Flexible evidence standards to improve access to cell therapies
Evidence, Pricing & Access (Track 1)
Adam Parnaby, Lead, Global Policy & Access, BMS
Mar 1714:15
Conference pass
Formulation and delivery of new modalities: Insight on viral formulation platforms
Viral Vector Manufacturing Sponsored by Fujifilm Diosynth Biotechnologies (Track 9)
Mar 1714:15
Conference pass
Gene modified cell therapy utilising gamma delta T-cells for the treatment of solid tumours
Gene Modified Cell Therapy (Track 8)
Daniel Fowler, Research Fellow, UCL
Mar 1714:15
Conference pass
Key learnings for developing a viable commercial strategy for young companies
Start-ups Showcase (Track 6)
Ilya Yasny, Partner, LanceBio Ventures
Mar 1714:15
Conference pass
Manufacturing approaches for exosome therapeutics
Cell Therapy Manufacturing (Track 10)
Dave Mentlak, Senior Scientist, Mesenbio
Mar 1714:15
Conference pass
Utilizing EU academic infrastructure for developing cell and gene therapies
Innovation (Track 2)
David Morrow, Senior Scientific Programme Manager-ATMP/Vaccines, EATRIS
Mar 1714:35
Conference pass
Development of a preventive dendritic cell vaccine for hereditary cancer
Immunotherapy (Track 5)
Gerty Schreibelt, Assistant Professor / Immunologist, Radboud University Medical Centre
Mar 1714:35
Conference pass
How SUSTAIN-HTA can contribute to JCA developments?
Evidence, Pricing & Access (Track 1)
Wim Goettsch, Special Advisor HTA & Professor for HTA of Pharmaceuticals, Zorginstituut
Mar 1714:35
Conference pass
On target biologic payload delivery using engineered gamma delta T-cells
Gene Modified Cell Therapy (Track 8)
Jonathan Fisher, Group Leader – Innate Immune Engineering Laboratory, University College London
Mar 1714:55
Conference pass
Access timelines & Challenges for ATMPs and Oncology medicines in the Netherlands vs surrounding countries
Evidence, Pricing & Access (Track 1)
Angela Borghouts - de Ruijter, Associate Director Market Access, Gilead Sciences
Mar 1714:55
Conference pass
Engineering Armored CAR-T Cells to Overcome the Leukemic Microenvironment
Immunotherapy (Track 5)
Marta Serafini, Associate Professor, School of Medicine and Surgery, University of Milano-Bicocca
Mar 1714:55
Conference pass
Engineering Optimized AAV Capsids via AI-Guided In Silico Design
Viral Vector Manufacturing Sponsored by Fujifilm Diosynth Biotechnologies (Track 9)
Hugh O'Brien, CTO, Lir Therapeutics
Mar 1714:55
Conference pass
Maintaining Genomic Integrity in Human Pluripotent Stem Cells for Advanced Therapies
Cell Therapy (Track 3)
Ivana Barbaric, Professor of Stem Cell Biology, The University of Sheffield
Mar 1714:55
Conference pass
Panel Discussion: Harnessing Technological Innovation to Optimise Supply Chain and Logistics in Advanced Therapies
Supply Chain & Logistics (Track 4)
Moderator: Brian Harrison, Director, Hitech Health
Holly Garlick, Head of GMP, Gene Therapy Innovation & Manufacturing Centre, University of Sheffield
Owen Bain, Director, Centre for Cell Gene Tissue Therapeutics, Royal Free NHS Trust
Ketki Vispute, Associate Director, MSAT, Autolus
Jay Feinberg, President, World Marrow Donor Association
Tara Sadeghi, Chief Operating Officer, Cellenkos Inc.
Mar 1714:55
Conference pass
Stem cell derived macrophages for next-gen immunotherapies
Gene Modified Cell Therapy (Track 8)
Nico Lachmann, Professor, Hannover Medical School
Mar 1714:55
Conference pass
The Extroducer and targeted delivery of clinical payloads: case studies
Innovation (Track 2)
Ricardo Baptista, Chief Technology Officer, Smartcella
Mar 1714:55
Conference pass
The impact of the new Point of Care and Modular manufacturing regulation on ATMP delivery in the UK
Cell Therapy Manufacturing (Track 10)
Anne Black, QA Specialist Pharmacist, NHS Specialist Pharmacy Service
Mar 1714:55
Conference pass
Update from Genethon: Applications of technological platforms
Gene Therapy (Track 7)
Angela Columbano, Head Business Development and Partnership, Genethon
Mar 1715:15
Conference pass
Converting immunosuppressive tumour microenvironment into an immunostimulatory one
Gene Modified Cell Therapy (Track 8)
Shao-An Xue, Professor, Zhengzhou University of Technology
Mar 1715:15
Conference pass
Leveraging collaborative efforts to address market access & HTA obstacles
Evidence, Pricing & Access (Track 1)
Josie Godfrey, Independent Market Access and Rare Disease Adviser, Independent Rare Disease Expert
Fleur Chandler, Patient Advocate and Health Economist, Duchenne U.K.
Mar 1715:15
Conference pass
Use of CAR-T Regs for the treatment of autoimmunity and transplantation
Immunotherapy (Track 5)
Marc Martinez-Llordella, Founder and VP Biology, Quell Therapeutics
Mar 1716:05
Conference pass
Chair’s Remarks: Paolo Morgese VP Public Affairs, Europe, Alliance for Regenerative Medicine
Evidence, Pricing & Access (Track 1)
Paolo Morgese, Vice President, Public Affairs, Europe, Alliance for Regenerative Medicine
Mar 1716:05
Conference pass
Chair's Remarks: Andrew Palfreeman, Associate Director, R&D Lab Core & Operations, Quell Therapeutics Ltd
Innovation (Track 2)
Andrew Palfreeman, Associate Director, R&D Lab Core and Operations, Quell Therapeutics
Mar 1716:05
Conference pass
Chair's Remarks: Arsalan Wafi, Academic Clinical Lecturer, King's College London
Cell Therapy (Track 3)
Arsalan Wafi, Academic Clinical Lecturer, King´s College London
Mar 1716:05
Conference pass
Chair's Remarks: Diana Hernandez, Director of Immune and Advanced Therapies, Anthony Nolan
Immunotherapy (Track 5)
Diana Hernandez, Director of Immune and Advanced Therapies, Anthony Nolan
Mar 1716:05
Conference pass
Chair's Remarks: Michelle Levene, Managing Director, 161 Consulting
Patient Engagement & Delivery (Track 4)
Michelle Levene, Managing Director, 161 Consulting Ltd
Mar 1716:05
Conference pass
Chair's Remarks: Nagy Habib, Head of R&D, Dawn Therapeutics & Professor of Surgery, Imperial College London
Gene Modified Cell Therapy (Track 8)
Nagy Habib, Professor of Surgery, Imperial College London
Mar 1716:05
Conference pass
Chair's Remarks: Paul Carter, Senior Director, MSAT, Quell Therapeutics Ltd
Cell Therapy Manufacturing (Track 10)
Paul Carter, Senior Director, MSAT, Quell Therapeutics
Mar 1716:05
Conference pass
Chair's Remarks: Paulo Fernandes, Senior Director, Technical Operations, Spur Therapeutics
Viral Vector Manufacturing Sponsored by Fujifilm Diosynth Biotechnologies (Track 9)
Paulo Fernandes, Senior Director, Technical Operations, Spur Therapeutics
Mar 1716:05
Conference pass
Chair's Remarks: Rahul Khetan, Venture Associate, UCB Ventures
Start-ups Showcase (Track 6)
Rahul Khetan, Venture Associate, UCB Ventures
Mar 1716:05
Conference pass
Chair's Remarks: Uta Griesenbach, Professor, National Heart And Lung Institute, Imperial College
Gene Therapy (Track 7)
Uta Griesenbach, Professor of Molecular Medicine, Imperial College London
Mar 1716:10
Conference pass
A not-for-profit approach to the pricing of an approved ex-vivo gene therapy
Evidence, Pricing & Access (Track 1)
Stefano Benvenuti, Head of Public Affairs and Market Access, Fondazione Telethon
Mar 1716:10
Conference pass
Academic proposal for market authorization of CAR-T cells
Gene Modified Cell Therapy (Track 8)
Manel Juan, Head of Immunology Service, Hospital Clínic de Barcelona
Mar 1716:10
Conference pass
Developing muscle specific gene therapy for rare neuromuscular disorders
Innovation (Track 2)
Annalucia Darbey, Postdoctoral Research Fellow, University College London
Mar 1716:10
Conference pass
Exploring the challenges of delivering immunotherapies at clinical sites
Immunotherapy (Track 5)
Mar 1716:10
Conference pass
Scouting for innovative gene & cell therapies
Gene Therapy (Track 7)
Hiro Usuda, Scouting & Transaction Lead, Business Development, Astellas
Mar 1716:10
Conference pass
Standardising the cell therapy field
Cell Therapy (Track 3)
Luke Lindsay-Hill, Head of Cell Therapy, Biotherapeutics Advanced Therapies, MHRA
Mar 1716:10
Conference pass
State of industry for manufacturing of ATMPs in the UK
Cell Therapy Manufacturing (Track 10)
Siddharth Subramaniam, Senior Policy and Public Affairs Executive, BIA
Mar 1716:10
Conference pass
Surviving the valley of death: How can young companies succeed?
Start-ups Showcase (Track 6)
Mar 1716:10
Conference pass
Suspension process for LVV manufacturing
Viral Vector Manufacturing Sponsored by Fujifilm Diosynth Biotechnologies (Track 9)
Chrysanthi Sitmalidou, Scientist II, Orchard therapeutics
Mar 1716:10
Conference pass
Trials and tribulations of setting up a ultra-rare diseases charity
Patient Engagement & Delivery (Track 4)
Mar 1716:30
Conference pass
Achieving a global approach to patient access for ATMPs and ultra-rare diseases
Patient Engagement & Delivery (Track 4)
Cem Zorlular, CEO, Er-Kim Pharmaceuticals
Mar 1716:30
Conference pass
ADC release mechanisms at the tumour
Immunotherapy (Track 5)
Marc de la Roche, Asst. Professor, Dept. of Biochemistry, University of Cambridge
Mar 1716:30
Conference pass
Considering launch in Rest of World? What to look out for in pricing and access beyond core markets
Evidence, Pricing & Access (Track 1)
Pedro Borga, Associate Director, Market Access and Pricing, Amicus Therapeutics
Mar 1716:30
Conference pass
Engineered bacteria to enhance immunotherapy responses
Gene Modified Cell Therapy (Track 8)
Pedro Correa de Sampaio, CEO, Neobe Therapeutics
Mar 1716:30
Conference pass
IMPACT: Irish Medicines Centre for Personalised Advanced Cellular Therapeutics
Cell Therapy (Track 3)
Athanasios (Sakis) Mantalaris, Professor, Trinity College Dublin
Mar 1716:50
Conference pass
Considerations for QC programme development in cell therapies
Cell Therapy Manufacturing (Track 10)
Mar 1716:50
Conference pass
Developing innovative cell therapies for solid tumours and autoimmune diseases in resource-constrained settings
Gene Modified Cell Therapy (Track 8)
Mar 1716:50
Conference pass
Developing technology for the long-term preservation of biologics
Innovation (Track 2)
Olivier Tramis, Senior Research Scientist, University of Strasbourg
Mar 1716:50
Conference pass
Development of iPSC derived CAR-NK Cells for Immunotherapy
Immunotherapy (Track 5)
Marina Tarunina, Research Director, Plasticell
Mar 1716:50
Conference pass
From start-up to a publicly traded company
Start-ups Showcase (Track 6)
Mar 1716:50
Conference pass
Integrated continuous biomanufacturing of AAVs
Viral Vector Manufacturing Sponsored by Fujifilm Diosynth Biotechnologies (Track 9)
Antonio Roldao, Head of Cell-based Vaccines Development Lab, IBET
Mar 1716:50
Conference pass
Latest update on Joint Clinical Assessments
Evidence, Pricing & Access (Track 1)
Matias Olsen, Senior Manager, Public Affairs & Policy, EUCOPE - European Confederation of Pharmaceutical Entrepreneurs
Mar 1716:50
Conference pass
Next generation gene writing platform for cell & gene therapies
Gene Therapy (Track 7)
Avencia Sánchez-Mejías García, CEO & Co-founder, Integra Therapeutics
Mar 1716:50
Conference pass
Realising the value of patient & public involvement
Patient Engagement & Delivery (Track 4)
Efstratia Papoutselou, Patient and Public Involvement Lead, Rinri Therapeutics
Mar 1716:50
Conference pass
Shaping the Future of Regenerative Medicine: Unlocking the potential of allogenic therapies
Cell Therapy (Track 3)
Kristian Tryggvason, Chief Executive Officer, Alder Therapeutics
Mar 1717:10
Conference pass
Antibody engineering to account for the tumour interface with the immune macroenvironment
Immunotherapy (Track 5)
Sophia Karagiannis, Professor of Translational Cancer Immunology and Immunotherapy, King's College London
Mar 1717:10
Conference pass
Engaging with industry to deliver treatment for Sickle Cell disease
Patient Engagement & Delivery (Track 4)
John James OBE, Chief Executive, Sickle Cell Society UK
Mar 1717:10
Conference pass
Exploring the regulatory challenges in a cell therapy environment
Cell Therapy (Track 3)
Mark Jarvis, Director of Advanced Therapies, Newcastle upon Tyne Hospitals NHS Foundation Trust
Mar 1717:10
Conference pass
The Mygotic Process™ The Next Advancement in Autologous Totipotent Stem Cells
Gene Modified Cell Therapy (Track 8)
Arthur Sagoskin, Chief Executive Officer & Co-Founder, Mygogenesis
Mar 1717:10
Conference pass
Trends in access barriers for advanced therapies in the UK
Evidence, Pricing & Access (Track 1)
Brad Groves, Director, NICE Advice, NICE
Mar 1717:10
Conference pass
Unified Healthcare Intelligence System (UHIS): An Empirical Study of AI-Driven Healthcare Optimization
Innovation (Track 2)
Raul Villamarin Rodriguez, Vice President, Woxsen University
Mar 1717:30
Conference pass
Panel Discussion: Advancing Cell Therapy Manufacturing: Embracing AI, Automation and Digitalisation
Cell Therapy Manufacturing (Track 10)
Moderator: Kat Kozyrytska, Founder, Cell Therapy Manufacturability Program
Luke Lindsay-Hill, Head of Cell Therapy, Biotherapeutics Advanced Therapies, MHRA
Ross Bunyan, External Manufacturing Lead, Resolution Therapeutics
Joseph Egan, Research Associate, Teesside University
Jorge Salazar, Head of Process Development, INmuneBio
Nan Zhang, Chief, Cell Therapy Manufacturing Section, Center for Cellular Engineering, National Institutes of Health
Mathias Svahn, Chief Executive Officer, NextCell Pharma
Mar 1717:30
Conference pass
Panel Discussion: Broader Applications for Gene Therapies
Gene Therapy (Track 7)
Moderator: Uta Griesenbach, Professor of Molecular Medicine, Imperial College London
Joanne Ng, Professor of Genetic Therapy, UCL Institute of Neurology
Eric Michael David, Chief Executive Officer of Gene Therapy, BridgeBio
Hiro Usuda, Scouting & Transaction Lead, Business Development, Astellas
Salmaan Dalvi, Chief Executive Officer, Global Regenerative Medicine Society
Azadeh Kia, VP Gene Therapy Research, Beacon Therapeutics
Alison Clare, Senior Research Associate, University of Bristol
Samantha Barber, Chief Executive Officer, Gene People
Mar 1717:30
Conference pass
Panel Discussion: Engaging with Patients to Improve Access and Affordability
Patient Engagement & Delivery (Track 4)
Moderator: Michelle Levene, Managing Director, 161 Consulting Ltd
Nicola Redfern, Director, NJ Redfern Ltd.
Sonia Valero, Head Of Clinical Operations - Patient Advocacy Leader, Vivet Therapeutics
Katja Berg, Global Value and Access Strategy, BBU, AstraZeneca
Efstratia Papoutselou, Patient and Public Involvement Lead, Rinri Therapeutics
Cem Zorlular, CEO, Er-Kim Pharmaceuticals
Josie Godfrey, Independent Market Access and Rare Disease Adviser, Independent Rare Disease Expert
Mar 1717:30
Conference pass
Panel Discussion: Exploring the Evolving Landscape of Viral Vector Manufacturing
Viral Vector Manufacturing Sponsored by Fujifilm Diosynth Biotechnologies (Track 9)
Moderator: Simon Briggs, Director, Advanced Analytics, Orchard therapeutics
Holger Laux, Director of Genetic Medicine, CSL Behring
Hugh O'Brien, CTO, Lir Therapeutics
Darren Nesbeth, Associate Professor, University College London
Sujith Sebastian, Viral Vector Hub Manager, Clinical Biotechnology Centre, NHSBT
Toby Gamlen, Head of Manufacturing, Gene Therapy Innovation and Manufacturing Centre, University of Sheffield
Antonio Roldao, Head of Cell-based Vaccines Development Lab, IBET
Mar 1717:30
Conference pass
Panel Discussion: Exploring the Latest Challenges and Opportunities for Cell Therapies
Cell Therapy (Track 3)
Moderator: David Kuntin, Chief Executive Officer, Mesenbio
Alejandro Madrigal, OBE FMedSci, Professor of Haematology, UCL Cancer Institute
Panteli Theocharous, Chief Therapeutics Officer and Head of Medical and Scientific Affairs, Stratus Therapeutics
Marcus Droege, Chief Commercial Officer, MUVON Therapeutics
Angela Borghouts - de Ruijter, Associate Director Market Access, Gilead Sciences
Arsalan Wafi, Academic Clinical Lecturer, King´s College London
Jeroen Rovers, Chief Medical Officer, Mendus
Mar 1717:30
Conference pass
Panel Discussion: New Frontiers in Cell Therapy: In-Vivo Engineering
Gene Modified Cell Therapy (Track 8)
Moderator: David Peritt, Chief Scientific Officer, Lupagen
Avencia Sánchez-Mejías García, CEO & Co-founder, Integra Therapeutics
Nico Lachmann, Professor, Hannover Medical School
Ash Toye, Professor of Cell Biology, University of Bristol & Co-founder, Scarlet Therapeutics, University of Bristol
Manel Juan, Head of Immunology Service, Hospital Clínic de Barcelona
Kerstin Papenfuss, Director Pharma, Deep Science Ventures
Nagy Habib, Professor of Surgery, Imperial College London
Mar 1717:30
Conference pass
Panel Discussion: Opportunities and Challenges of Investing in ATMPs: Insight on the Latest European and Global Trends
Innovation (Track 2)
Moderator: Sven Kili, Partner, Saisei Ventures
Owen Smith, Partner, 4BIO CAPITAL
Kristian Tryggvason, Chief Executive Officer, Alder Therapeutics
Pedro Correa de Sampaio, CEO, Neobe Therapeutics
Leigh Brody, Investment Manager, AlbionVC
Andrew Roddam, Chief Business Development Officer, EveryONE Medicines
Lutz Bonacker, Former Senior Vice President and General Manager, CSL Behring
Mar 1717:30
Conference pass
Panel Discussion: Perspectives on the EU Joint Health Technology Assessment: Is the JCA fit for purpose?
Evidence, Pricing & Access (Track 1)
Moderator: Matias Olsen, Senior Manager, Public Affairs & Policy, EUCOPE - European Confederation of Pharmaceutical Entrepreneurs
Dilip Patel, SVP, Access & Market Development, Autolus
Henriette Burghoorn, Associate Director, Market Access, Gilead Sciences
Paolo Morgese, Vice President, Public Affairs, Europe, Alliance for Regenerative Medicine
Rosie Lindup, Senior Policy and Public Affairs Manager, BioIndustry Association (BIA)
Brett Doble, Director HEOR, Australia/Canada/Europe (ACE), HEOR Center of Excellence, Kite, a Gilead Company
Mar 1717:30
Conference pass
Panel Discussion: Revolutionising Cancer Treatment: Innovations in Immunotherapy
Immunotherapy (Track 5)
Marc de la Roche, Asst. Professor, Dept. of Biochemistry, University of Cambridge
Margareth Jorvid, Board Member, Elicera Therapeutics
Sophia Karagiannis, Professor of Translational Cancer Immunology and Immunotherapy, King's College London
Shao-An Xue, Professor, Zhengzhou University of Technology
Mar 1717:30
Conference pass
Panel Discussion: Top Tips for Attracting Investment
Start-ups Showcase (Track 6)
Moderator: Rahul Khetan, Venture Associate, UCB Ventures
Ilya Yasny, Partner, LanceBio Ventures
Jean-Philippe Combal, Co-Founder & Chief Executive Officer, Vivet Therapeutics
Natalie Johnston, Principal, 4BIO CAPITAL
Victor Hernandez, CSO, Axovia therapeutics
Simon Waddington, Professor of Gene Therapy, UCL
Create your personal agenda –check the favourite icon
Mar 189:05
Conference pass
The Day After: Turning Headlines into Value in Biotech M&A
Keynotes
Joshi Venugopal, General Manager and Head of Europe, Novartis Gene Therapies
Mar 189:45
Conference pass
Delivering next generation regenerative medicine through bioengineering
Keynotes
Mar 1811:05
Conference pass
Chair's Remarks: Amanda-Jayne Carr, Associate Professor, UCL Institute of Ophthalmology
Cell Therapy (Track 3)
Amanda Jayne Carr, Associate Professor, Institute of Ophthalomolgy U.C.L.
Mar 1811:05
Conference pass
Chair's Remarks: David James, Professor of Bioengineering, Sheffield University
Innovation (Track 2)
David James, Professor of Bioprocess Engineering, University of Sheffield
Mar 1811:05
Conference pass
Chair's Remarks: Gaurav Bhavsar, Technical Director, Gene Therapy Vector Facility (GTVF), King’s College London
Viral Vector Manufacturing Sponsored by Fujifilm Diosynth Biotechnologies (Track 9)
Gaurav Bhavsar, Technical Director, Gene Therapy Vector Facility (GTVF), King's College London
Mar 1811:05
Conference pass
Chair's Remarks: Heather Main, Co-founder, HOYA Consulting
Cell Therapy Manufacturing (Track 10)
Heather Main, Co-Founder, HOYA consulting
Mar 1811:05
Conference pass
Chair's Remarks: Inês Leal Reis, Co-founder, Regenera
Clinical Development (Track 4)
Inês Leal Reis, Co-founder, Regenera
Mar 1811:05
Conference pass
Chair's Remarks: Marcello Maresca, Senior Director - Genome Engineering, AstraZeneca
Gene Modified Cell Therapy (Track 8)
Marcello Maresca, Senior Director - Genome Engineering, AstraZeneca
Mar 1811:05
Conference pass
Chair's Remarks: Michael Kyriakides, Principal, Syncona
Start-ups Showcase (Track 6)
Michael Kyriakides, Principal, Syncona Ltd
Mar 1811:05
Conference pass
Chair's Remarks: Roberto Nitsch, Director, AstraZeneca
Gene Editing (Track 5)
Roberto Nitsch, Director, AstraZeneca
Mar 1811:05
Conference pass
Chair's Remarks: Vicki Coutinho, Managing Director & Consultant, Geni Consulting
Regulation (Track 1)
Vicki Coutinho, Managing Director & Consultant, Geni Consulting
Mar 1811:05
Conference pass
Chair's Remarks: Vikash Reebye, Head of Academic Partnerships, MiNA Therapeutics Ltd.
Gene Therapy (Track 7)
Vik Reebye, Head of Academic Partnership, MiNA Therapeutics Ltd
Mar 1811:10
Conference pass
AAV platform process development
Viral Vector Manufacturing Sponsored by Fujifilm Diosynth Biotechnologies (Track 9)
Gaurav Bhavsar, Technical Director, Gene Therapy Vector Facility (GTVF), King's College London
Mar 1811:10
Conference pass
Achieving early-stage clinical success
Clinical Development (Track 4)
Mar 1811:10
Conference pass
Development of integrative gene therapy technologies
Gene Therapy (Track 7)
John Counsell, Associate Professor, UCL
Mar 1811:10
Conference pass
Drug screening for HDR
Gene Editing (Track 5)
Anna-Lina Cavallo, Director Discovery Cell and Gene Therapy integrated Bioanalysis, AstraZeneca
Mar 1811:10
Conference pass
From idea to reality: How do you spin out a new cell therapy platform?
Start-ups Showcase (Track 6)
Ash Toye, Professor of Cell Biology, University of Bristol & Co-founder, Scarlet Therapeutics, University of Bristol
Mar 1811:10
Conference pass
Global manufacturing footprint from build to commercial scale-up
Cell Therapy Manufacturing (Track 10)
Sarah Snykers, Head of Operations, Legend Biotech
Mar 1811:10
Conference pass
Improving Prime Editing Repair Outcomes by DNA Repair Modulation
Gene Modified Cell Therapy (Track 8)
Marcello Maresca, Senior Director - Genome Engineering, AstraZeneca
Mar 1811:10
Conference pass
Putting the patient front and centre: Delivering on the promise of cell therapies
Cell Therapy (Track 3)
Panteli Theocharous, Chief Therapeutics Officer and Head of Medical and Scientific Affairs, Stratus Therapeutics
Mar 1811:10
Conference pass
Regulatory update on ATMPs: Adapting to the evolving landscape
Regulation (Track 1)
Amina Al-Mossawi, Qualified Person, MeiraGTx
Mar 1811:10
Conference pass
Treating 1 in 2500: Tackling diseases of the peripheral nervous system
Innovation (Track 2)
Katherine Forsey, Chief Research Officer, Charcot Marie Tooth Association
Mar 1811:30
Conference pass
Beyond the protocol: Setting yourself up for clinical trial success
Clinical Development (Track 4)
Mar 1811:30
Conference pass
Modified cell therapies to overcome solid tumours
Gene Modified Cell Therapy (Track 8)
Benjamin Taylor, Senior Director, Cell Therapy Biotechnologies, AstraZeneca
Mar 1811:30
Conference pass
Stem cell derived extracellular vesicles as a substitute for cell therapy
Cell Therapy (Track 3)
Mar 1811:50
Conference pass
Autologous and allogenic CAR-Ts for haematological and solid tumours
Gene Modified Cell Therapy (Track 8)
Stefanos Theoharis, Chief Executive Officer, OneChain Immunotherapeutics
Mar 1811:50
Conference pass
Developing therapeutics oligonucleotides for reactivating genes
Gene Therapy (Track 7)
Vik Reebye, Head of Academic Partnership, MiNA Therapeutics Ltd
Mar 1811:50
Conference pass
Development of skills and training resources: Insight from the Innovation Hub for Gene Therapy
Innovation (Track 2)
Janine Kirby, Professor, University of Sheffield
Mar 1811:50
Conference pass
Enabling high-throughput production of uniform cell aggregates by harnessing in-air microfluidics
Start-ups Showcase (Track 6)
Tom Kamperman, Founder & CTO, IamFluidics BV
Mar 1811:50
Conference pass
Exosomes for targeted drug delivery: Unlocking the potential of gene editing complexes
Gene Editing (Track 5)
Samantha Thomas, Head of Research, ReNeuron
Mar 1811:50
Conference pass
Novel expansion strategy for NK cells
Cell Therapy (Track 3)
Oliver Spadiut, Head of the Research Area Biochemical Engineering, TU Wien
Mar 1811:50
Conference pass
Regulatory Approval & Quality Assessment of ATMPs
Regulation (Track 1)
Janet Glassford, Expert Quality Assessor, Biologicals Unit, Medicines & Healthcare products Regulatory Agency
Mar 1811:50
Conference pass
Stem cell application in musculoskeletal disorders
Clinical Development (Track 4)
Inês Leal Reis, Co-founder, Regenera
Mar 1811:50
Conference pass
The master file model for qualifying materials
Cell Therapy Manufacturing (Track 10)
Heather Main, Co-Founder, HOYA consulting
Mar 1812:10
Conference pass
A unique immuno-modulatory platform to rejuvenate immune competence & overcome treatment resistance
Cell Therapy (Track 3)
Alex Blyth, Founder & CEO, Lift Biosciences Ltd
Mar 1812:10
Conference pass
Analytical methods for oncolytic viruses and their use to elucidate structure function relations
Viral Vector Manufacturing Sponsored by Fujifilm Diosynth Biotechnologies (Track 9)
Johannes Solzin, Laboratory Head, Analytical Development, ATMPs, Boehringer Ingelheim
Mar 1812:10
Conference pass
Cell free stem cell therapy 2.0: Clinical potential of MSC-EVs
Start-ups Showcase (Track 6)
Bernd Giebel, Professor, University Hospital Essen
Mar 1812:10
Conference pass
Challenges and strategies for the development of a bicistronic AAV gene therapy for ocular disorders
Gene Therapy (Track 7)
Emily Warner, VP, Technical Operations, ikarovec
Mar 1812:10
Conference pass
Critical considerations for successful ATMP development: Academic bench to commercial bedside
Clinical Development (Track 4)
Mark Lowdell, CSO, INmuneBio
Mar 1812:10
Conference pass
How to create the optimal immune milieu for optimal effect Immune Effector Cells
Gene Modified Cell Therapy (Track 8)
Jaap Jan Boelens, Chief, Transplantation and Cellular Therapies, Memorial Sloan-Kettering Cancer Center
Mar 1812:10
Conference pass
Quality control considerations in iPSC gene editing
Gene Editing (Track 5)
Pia Johansson, Director, Cell and Gene Therapy Core, Lund University
Mar 1813:30
Conference pass
Chair's Remarks: Heather Main, Co-founder, HOYA Consulting
Cell Therapy Manufacturing (Track 10)
Heather Main, Co-Founder, HOYA consulting
Mar 1813:30
Conference pass
Chair's Remarks: Manal Mohammed, Senior Lecturer (Medical Microbiology), University of Westminster
Innovation (Track 2)
Manal Mohammed, Senior Lecturer (Medical Microbiology), University of Westminster
Mar 1813:30
Conference pass
Chair's Remarks: Marcello Maresca, Senior Director - Genome Engineering, AstraZeneca
Gene Modified Cell Therapy (Track 8)
Marcello Maresca, Senior Director - Genome Engineering, AstraZeneca
Mar 1813:30
Conference pass
Chair's Remarks: Michael Kyriakides, Principal, Syncona
Start-ups Showcase (Track 6)
Michael Kyriakides, Principal, Syncona Ltd
Mar 1813:30
Conference pass
Chair's Remarks: Patrick Hopkinson, Independent HTA Expert
Cell Therapy (Track 3)
Mar 1813:30
Conference pass
Chair's Remarks: Paul Gissen, Professor in Paediatric Metabolic Diseases, University College London and Great Ormond Street Hospital
Clinical Development (Track 4)
Mar 1813:30
Conference pass
Chair's Remarks: Piers Walser, Research Scientist, Clinical Biotechnology Centre, NHS Blood and Transplant
Viral Vector Manufacturing Sponsored by Fujifilm Diosynth Biotechnologies (Track 9)
Piers Walser, Lead Development Scientist, Clinical Biotechnology Centre, NHSBT
Mar 1813:30
Conference pass
Chair's Remarks: Roberto Nitsch, Director, AstraZeneca
Gene Editing (Track 5)
Roberto Nitsch, Director, AstraZeneca
Mar 1813:30
Conference pass
Chair's Remarks: Sara Benedetti, Group Leader, Assistant Professor in Gene Therapy, UCL
Gene Therapy (Track 7)
Sara Benedetti, Group Leader, Assistant Professor in Gene Therapy, University College London
Mar 1813:30
Conference pass
Chair's Remarks: Vicki Coutinho, Managing Director & Consultant, Geni Consulting
Regulation (Track 1)
Vicki Coutinho, Managing Director & Consultant, Geni Consulting
Mar 1813:35
Conference pass
Development of viral plasmids for AAV manufacturing
Viral Vector Manufacturing Sponsored by Fujifilm Diosynth Biotechnologies (Track 9)
Piers Walser, Lead Development Scientist, Clinical Biotechnology Centre, NHSBT
Mar 1813:35
Conference pass
Ongoing research into Gene Therapy Standards
Gene Therapy (Track 7)
Claire Kerridge, Head of Gene Therapy, MHRA
Mar 1813:35
Conference pass
Panel Discussion: Autologous vs. Allogeneic Approaches
Gene Modified Cell Therapy (Track 8)
Moderator: Stefanos Theoharis, Chief Executive Officer, OneChain Immunotherapeutics
Mathias Kroll, Chief Business Officer, Cynata Therapeutics Ltd
Diana Hernandez, Director of Immune and Advanced Therapies, Anthony Nolan
Mark Lowdell, CSO, INmuneBio
Arthur Sagoskin, Chief Executive Officer & Co-Founder, Mygogenesis
Jiri Eitler, Group Leader - NK Cell Therapy, Dresden University of Technology
Mar 1813:35
Conference pass
Panel Discussion: Building the ATMP Workforce of the Future: Improving Skills, Diversity and Training
Innovation (Track 2)
Moderator: Anji Miller, Skills Lead, Innovation Hubs for Gene Therapies/Programme Director, Translational Skills, LifeArc
Nicola Ambler, Founder, The CGT Circle
Tanya Patel, Senior Manager CTSM, Biontech
Katy Newton, Chief Scientific Officer, MFX
Kerstin Kinkelin, Innovation Lead, Bristol BioDesign Institute, University of Bristol
Kate Barclay, Skills Strategy Consultant, UK Bioindustry Association
Manal Mohammed, Senior Lecturer (Medical Microbiology), University of Westminster
Mar 1813:35
Conference pass
Panel Discussion: Considerations for Successful Clinical Trial Design
Clinical Development (Track 4)
Rachel Haines, VP, Clinical Development and Operations, Rinri Therapeutics
Katherine Forsey, Chief Research Officer, Charcot Marie Tooth Association
Beatriz Duran, Head of Clinical Trials Pharmacy Service and ATMPs, Manchester University NHS Foundation Trust
Sonia Valero, Head Of Clinical Operations - Patient Advocacy Leader, Vivet Therapeutics
Roger Legtenberg, Co-Founder, Partners4Patients Foundation
Carolyn Chan, Senior Specialist Clinical Trials (ATIMPs) and QA Pharmacist, Great Ormond Street Hospital
Victor Hernandez, CSO, Axovia therapeutics
Mar 1813:35
Conference pass
Panel Discussion: How can the Uptake of Approved CAR-T Therapies be Improved: Addressing Supply Costs, Access and Other Barriers?
Cell Therapy (Track 3)
Ulf Holmgren, Global Pricing and Market Access Director, Astrazeneca
Adam Parnaby, Lead, Global Policy & Access, BMS
Jaap Jan Boelens, Chief, Transplantation and Cellular Therapies, Memorial Sloan-Kettering Cancer Center
Omer Dushek, Professor of Molecular Immunology, University of Oxford
Renaud Vaillant, CEO & co-Founder, Alaya.bio
Mar 1813:35
Conference pass
Panel Discussion: Innovation In Gene Editing - Leveraging Platform Technology to Enhance Development Efficiency
Gene Editing (Track 5)
Moderator: Randolph Corteling, Chief Scientific Officer, ReNeuron
Claudio Mussolino, Group Leader - Genome and Epigenome Engineering, Freiburg University Medical Center
Roberto Nitsch, Director, AstraZeneca
Pia Johansson, Director, Cell and Gene Therapy Core, Lund University
Melita Irving, Group Leader at the Ludwig Institute for Cancer Research, University of Lausanne
Dominic Schmidt, General Partner, Advent Life Sciences
Tom Payne, Chief Operating Officer, Laverock Therapeutics
Cecile Bauche, Chief Scientific Officer, Alaya.bio
Mar 1813:35
Conference pass
Panel Discussion: Key Learnings for Successful Company Creation and Spinning Out
Start-ups Showcase (Track 6)
Moderator: Leigh Brody, Investment Manager, AlbionVC
James Levine, President, Fondation Ipsen
Oliver Spadiut, Head of the Research Area Biochemical Engineering, TU Wien
Pamela Tranter, Head, Translational Research Group (TRO), University College London
Dominic O'Regan, Business Development Consultant & Investor, New Mosaic
Jean-Philippe Combal, Co-Founder & Chief Executive Officer, Vivet Therapeutics
Michael Kyriakides, Principal, Syncona Ltd
Mar 1813:35
Conference pass
Panel Discussion: Manufacturing Strategies: Decentralised Vs. Centralised Approaches for Cell Therapies
Cell Therapy Manufacturing (Track 10)
Moderator: Kat Kozyrytska, Founder, Cell Therapy Manufacturability Program
Sandeep Kumar, Head of Advanced Therapy Production, Guy's and St Thomas' NHS Foundation Trust
Sarah Snykers, Head of Operations, Legend Biotech
Stephen Sullivan, Director, Lindville Bio
Urvi Thacker, Associate Director, MSAT, Quell Therapeutics
Valentin von Werz, PhD Researcher, TU Wien
Lilian Hook, Director of Cell, Aphaeresis and Gene Therapies, NHS Blood and Transplant
Lior Raviv, CTO, Pluri
Mar 1813:35
Conference pass
Panel Discussion: Navigating the Global Regulatory Landscape for Commercial Approval
Regulation (Track 1)
Moderator: Vicki Coutinho, Managing Director & Consultant, Geni Consulting
Sean Russell, Head of Regulatory Affairs, Telethon Foundation
David Uguen, SVP, Head of Regulatory Affairs, Orchard therapeutics
Amina Al-Mossawi, Qualified Person, MeiraGTx
Anna Koptina, Head Of Regulatory Affairs, Mendus
Janet Glassford, Expert Quality Assessor, Biologicals Unit, Medicines & Healthcare products Regulatory Agency
Kathryn Parsley, VP, Regulatory Affairs, Complement Therapeutics
Mar 1813:55
Conference pass
Designing next generation adsorbent materials for viral vector manufacturing
Gene Therapy (Track 7)
George Pamenter, Researcher, UCL
Mar 1813:55
Conference pass
Lentiviral vector manufacturing
Viral Vector Manufacturing Sponsored by Fujifilm Diosynth Biotechnologies (Track 9)
Noor Mujahid, Head of Vector Process Development, NHS Centre for Cell Gene and Tissue Therapeutics
Mar 1814:15
Conference pass
Automated CAR-T manufacturing assisted by AI
Cell Therapy Manufacturing (Track 10)
Laura Herbst, Group Manager, Fraunhofer-Institute for Production Technology
Julius Mathews, Group Manager, Fraunhofer Institute for Production Technology IPT
Mar 1814:15
Conference pass
Building an innovation ecosystem in Manchester to accelerate idea to revenue
Start-ups Showcase (Track 6)
Aline Miller, Professor, The University of Manchester
Mar 1814:15
Conference pass
CRISPR modification of NK cells
Gene Modified Cell Therapy (Track 8)
Diana Hernandez, Director of Immune and Advanced Therapies, Anthony Nolan
Mar 1814:15
Conference pass
Curing blindness: Cell therapy for AMD
Cell Therapy (Track 3)
Amanda Jayne Carr, Associate Professor, Institute of Ophthalomolgy U.C.L.
Mar 1814:15
Conference pass
Enabling precision editing through modified CRISPR Cas systems
Gene Editing (Track 5)
Claudio Mussolino, Group Leader - Genome and Epigenome Engineering, Freiburg University Medical Center
Mar 1814:15
Conference pass
Perspectives from pharmacy: Accelerating clinical trials set-up and delivery
Clinical Development (Track 4)
Beatriz Duran, Head of Clinical Trials Pharmacy Service and ATMPs, Manchester University NHS Foundation Trust
Mar 1814:15
Conference pass
Unpicking AAV ocular inflammation to improve outcomes for gene therapy
Gene Therapy (Track 7)
Alison Clare, Senior Research Associate, University of Bristol
Mar 1814:15
Conference pass
Using lipid systems biology towards diagnostic and therapeutic gain
Innovation (Track 2)
Sheba Jarvis, Post CCT Post Doctoral Fellow, Imperial College London
Mar 1815:05
Conference pass
Chair's Remarks: Abdullah Khan, Radcliffe Department of Medicine Principal Investigator, MRC WIMM Research Fellow, University of Oxford
Innovation (Track 2)
Abdullah Khan, Radcliffe Department of Medicine Principal Investigator, MRC WIMM Research Fellow, University of Oxford
Mar 1815:05
Conference pass
Chair's Remarks: Claudiu Cozmescu, Postdoctoral Researcher, Gissen Lab, UCL
Viral Vector Manufacturing Sponsored by Fujifilm Diosynth Biotechnologies (Track 9)
Claudiu Cozmescu, Postdoctoral Researcher, Gissen Lab, University College London
Mar 1815:05
Conference pass
Chair's Remarks: Darius Widera, Professor of Stem Cell Biology and Regenerative Medicine, University of Reading
Cell Therapy (Track 3)
Mar 1815:05
Conference pass
Chair's Remarks: Giandomenico Turchiano, Associate Director, Cell & Gene therapy Safety, AstraZeneca
Gene Editing (Track 5)
Giandomenico Turchiano, Associate Director, Cell & Gene therapy Safety, AstraZeneca
Mar 1815:05
Conference pass
Chair's Remarks: Giovanni Rizzo, Partner Biotech Fund, Indaco Venture Partners
Start-ups Showcase (Track 6)
Giovanni Rizzo, Partner Biotech Fund, Indaco Venture Partners
Mar 1815:05
Conference pass
Chair's Remarks: Heather Main, Co-founder, HOYA Consulting
Cell Therapy Manufacturing (Track 10)
Heather Main, Co-Founder, HOYA consulting
Mar 1815:05
Conference pass
Chair's Remarks: Jaap Boelens, Chief Stem Cell Transplantation & Cellular Therapies Pediatrics, Memorial Sloan Kettering Cancer Center
Clinical Development (Track 4)
Jaap Jan Boelens, Chief, Transplantation and Cellular Therapies, Memorial Sloan-Kettering Cancer Center
Mar 1815:05
Conference pass
Chair's Remarks: Marcello Maresca, Senior Director - Genome Engineering, AstraZeneca
Gene Modified Cell Therapy (Track 8)
Marcello Maresca, Senior Director - Genome Engineering, AstraZeneca
Mar 1815:05
Conference pass
Chair's Remarks: Sara Benedetti, Group Leader, Assistant Professor in Gene Therapy, UCL
Gene Therapy (Track 7)
Sara Benedetti, Group Leader, Assistant Professor in Gene Therapy, University College London
Mar 1815:05
Conference pass
Chair's Remarks: Vicki Coutinho, Managing Director & Consultant, Geni Consulting
Regulation (Track 1)
Vicki Coutinho, Managing Director & Consultant, Geni Consulting
Mar 1815:10
Conference pass
Accelerating the discovery of novel CAR-T
Clinical Development (Track 4)
Mar 1815:10
Conference pass
Assessing the clinical efficacy of immunotherapies using engineered human model systems
Innovation (Track 2)
Abdullah Khan, Radcliffe Department of Medicine Principal Investigator, MRC WIMM Research Fellow, University of Oxford
Mar 1815:10
Conference pass
Decentralised CAR-T manufacturing
Cell Therapy (Track 3)
Lilian Hook, Director of Cell, Aphaeresis and Gene Therapies, NHS Blood and Transplant
Mar 1815:10
Conference pass
Developing CAR-T therapies
Gene Modified Cell Therapy (Track 8)
Evangelia Kokalaki, Director, Immunobiology, Autolus Therapeutics
Mar 1815:10
Conference pass
Diagnosing and addressing manufacturing bottle necks
Start-ups Showcase (Track 6)
Adam Brown, Co-founder and CTO, SynGenSys & Associate Professor of Biopharmaceutical Engineering, The University of Sheffield
Mar 1815:10
Conference pass
Epigenome editing for allogenic CAR-T cells
Gene Therapy (Track 7)
Federica Zinghirino, Postdoctoral Research Fellow, UCL
Mar 1815:10
Conference pass
Genomic stability and DNA repair after gene editing
Gene Editing (Track 5)
Giandomenico Turchiano, Associate Director, Cell & Gene therapy Safety, AstraZeneca
Mar 1815:10
Conference pass
In vivo lentiviral gene therapy for cholestatic disorders
Viral Vector Manufacturing Sponsored by Fujifilm Diosynth Biotechnologies (Track 9)
Claudiu Cozmescu, Postdoctoral Researcher, Gissen Lab, University College London
Mar 1815:10
Conference pass
Latest update on EU policies for ATMP development
Regulation (Track 1)
Giulia Leonetti, Policy Officer, European Commission
Mar 1815:10
Conference pass
Process development and intensification of NK cell production in stirred tank bioreactors
Cell Therapy Manufacturing (Track 10)
Valentin von Werz, PhD Researcher, TU Wien
Mar 1815:30
Conference pass
Compassionate Use and Transition of Care for Paediatric Patients
Clinical Development (Track 4)
Hamza Patel, Lead Advanced Therapies (Cell & Gene) Specialist Clinical Trial Pharmacist, Great Ormond Street Hospital for Children
Carolyn Chan, Senior Specialist Clinical Trials (ATIMPs) and QA Pharmacist, Great Ormond Street Hospital
Mar 1815:30
Conference pass
Developing a perfusion process for lentiviral vector manufacturing
Viral Vector Manufacturing Sponsored by Fujifilm Diosynth Biotechnologies (Track 9)
Marta Arrizabalaga Cascallana, PhD Researcher, UCL
Mar 1815:30
Conference pass
Engineering next generation T-cells for cancer immunotherapy
Gene Modified Cell Therapy (Track 8)
Melita Irving, Group Leader at the Ludwig Institute for Cancer Research, University of Lausanne
Mar 1815:30
Conference pass
From academic research to innovative ideas: Turning research into meaningful results
Innovation (Track 2)
Kerstin Kinkelin, Innovation Lead, Bristol BioDesign Institute, University of Bristol
Mar 1815:30
Conference pass
Gene editing to the retina: From in vivo to 3D retinal organoids
Gene Editing (Track 5)
Juliette Pulman, Research Fellow, INSERM
Mar 1815:30
Conference pass
Going further: Cynata’s pursuit of developing potent regenerative cell therapies for global use
Cell Therapy (Track 3)
Mathias Kroll, Chief Business Officer, Cynata Therapeutics Ltd
Mar 1815:30
Conference pass
Targeting the blood-brain barrier to improve CNS delivery of hematopoietic stem cell gene therapy for metabolic disorders
Gene Therapy (Track 7)
Sara Benedetti, Group Leader, Assistant Professor in Gene Therapy, University College London
Mar 1815:30
Conference pass
The Latest Developments in Regulation for Advanced Therapy Medicinal Products
Regulation (Track 1)
Anna Koptina, Head Of Regulatory Affairs, Mendus
Mar 1815:30
Conference pass
The need for bespoke quality analytics in developing iPS cell therapeutics
Cell Therapy Manufacturing (Track 10)
Stephen Sullivan, Director, Lindville Bio
Mar 1815:30
Conference pass
Using AI to develop personalised cancer vaccines
Start-ups Showcase (Track 6)
Prasun Chakraborty, CEO and Founder, Genevation LTD
Mar 1815:50
Conference pass
AAV gene therapies: Solving the challenge of neutralising antibodies
Start-ups Showcase (Track 6)
George Frodsham, Founder & CEO, MediSieve Limited
Mar 1815:50
Conference pass
AI-Driven Excellence in GMP Manufacturing: Transforming Quality and Operations
Innovation (Track 2)
Owen Bain, Director, Centre for Cell Gene Tissue Therapeutics, Royal Free NHS Trust
Mar 1815:50
Conference pass
Development of innovative in vivo CAR-T therapies: From the bench to the clinic
Clinical Development (Track 4)
Renaud Vaillant, CEO & co-Founder, Alaya.bio
Mar 1815:50
Conference pass
Error-free genome editing for eradication of life-threatening persistent virus infections
Gene Editing (Track 5)
Niklas Beschorner, Head of R&D, PROVIREX Genome Editing Therapies GmbH
Mar 1815:50
Conference pass
Latest insight from King’s College London Gene Therapy Vector Facility
Viral Vector Manufacturing Sponsored by Fujifilm Diosynth Biotechnologies (Track 9)
Simon Walker, Head of MSAT, Gene Therapy Vector Facility, Kings College London
Mar 1815:50
Conference pass
Leveraging technological innovation to support allogenic manufacturing
Cell Therapy Manufacturing (Track 10)
Lior Raviv, CTO, Pluri
Mar 1815:50
Conference pass
Optimising the antigen sensitivity of CAR-T cells
Cell Therapy (Track 3)
Omer Dushek, Professor of Molecular Immunology, University of Oxford
Mar 1815:50
Conference pass
Programmable gene silencing technology for next-generation advanced therapy development
Gene Modified Cell Therapy (Track 8)
Tom Payne, Chief Operating Officer, Laverock Therapeutics
Mar 1815:50
Conference pass
Requirements for Governance and Preparation of Gene Therapy
Gene Therapy (Track 7)
Nicola Stoner, Consultant Pharmacist - Cancer & ATMPs, Oxford University Hospitals NHS Foundation Trust
Mar 1815:50
Conference pass
The Importance of Interacting with Regulators
Regulation (Track 1)
Margareth Jorvid, Board Member, Elicera Therapeutics
last published: 02/Jul/25 12:55 GMT
Get Involved with Advanced Therapies Congress
Created by
Terrapinn is proud to be a member of isla.
Working together to build sustainable events